Since BIRC5 is reported to be an immune-associated gene that promotes tumor progression, many studies related to survivin in NSCLC focus on the sensitization to chemotherapy, radiotherapy, and targeted therapy, with little success achieved due the heterogeneity of this disease [19,20]. This evidence concerns the gene BIRC5 and neoplasm.